Online inquiry

IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9934MR)

This product GTTS-WQ9934MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets EPHA3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005233.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2042
UniProt ID P29320
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ9934MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5083MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ5337MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ2500MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 212
GTTS-WQ3517MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BART
GTTS-WQ13834MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-10987
GTTS-WQ7584MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA G-CSF
GTTS-WQ9972MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA KD-247
GTTS-WQ7166MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW